Chronic hepatitis c
Conditions
Interventions
Group A:Grazoprevir/elbasvir
Group B:Sofosbuvir and velpatasvir
Sponsors
Department of Gastroenterology, Xinqiao Hospital, Affiliated to Military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 65 years; (2) in accordance with the Chinese medical association of liver disease, hepatitis c and update (2015 edition) of the criteria for the diagnosis of chronic hepatitis c, including treated first or by the governance and relapse cases; (3) the HCV RNA can be measured; (4) the Child - Pugh, grade A level; (5) the elastic monitoring or liver fibrosis liver enzyme spectrum determination consider liver fibrosis; (6) always merge in the treatment of the disease, did not have serious drug interactions with the study drug; (7) no DAA previous history of drug treatment; (8) patients agreed to participate in the study, and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) in patients with liver failure, liver cancer; (2) the merger's liver virus is carried; (3) for the treatment of damaged liver function during clear (ALT 10 times greater than the ULN or bilirubin, alkaline phosphatase, INR significantly higher); (4) pregnancy or short term pregnancy planning stage of reproductive age women and breast milk of women; (5) the subjective is not willing to continue to complete clinical research; (6) during the treatment of schizophrenia or depression patients, or patients with severe depression, mental symptoms during treatment; (7) drug intolerance, basic diseases drugs and drug has serious interaction in this study; (8) serious big organ failure (heart, lung, kidney, etc.), severe infection and diseases of the retina; (9) slow heart beat (bradycardia) and ery serious patients with conduction block and take amiodarone; (10) alcoholism, compulsive drug, drug use and has yet to drug addicts; (11) serious insomnia; (12) uncontrolled hypertension, uncontrolled diabetes, autoimmune disease of control, uncontrolled thyroid disease; (13) during treatment for high accuracy operation patients; (14) comprehensive evaluation, poor compliance; (15) Be included in the study before the other test drugs or is involved in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver fiber; | — |
Countries
China
Contacts
Public ContactYongbing Zhao
Xinqiao Hospital of Army Military University
Outcome results
None listed